Inhibition of thrombin activity with DNA-aptamers.
The effects of two DNA aptamers (oligonucleotides) 15TBA and 31TBA (15- and 31-mer thrombin-binding aptamers, respectively) on thrombin activity were studied. Both aptamers added to human plasma dose-dependently increased thrombin time (fibrin formation upon exposure to exogenous thrombin), prothrombin time (clotting activation by the extrinsic pathway), and activated partial thromboplastin time (clotting activation by the intrinsic pathway). At the same time, these aptamers did not modify amidolytic activity of thrombin evaluated by cleavage of synthetic chromogenic substrate. Aptamers also inhibited thrombin-induced human platelet aggregation. The inhibitory effects of 31TBA manifested at lower concentrations than those of 15TBA in all tests. These data indicate that the studied antithrombin DNA aptamers effectively suppress its two key reactions, fibrin formation and stimulation of platelet aggregation, without modifying active center of the thrombin molecule.
Dobrovolsky
A B
AB
Russian Cardiology Research-and-Production Complex, Federal Agency for Health Care and Social Development, M. V. Lomonosov Moscow State University, Russia.
Titaeva
E V
EV
Khaspekova
S G
SG
Spiridonova
V A
VA
Kopylov
A M
AM
Mazurov
A V
AV
D000991:Antithrombins / Q000494:pharmacology*; D052157:Aptamers, Nucleotide / Q000737:chemistry / Q000494:pharmacology*; D001483:Base Sequence; D004305:Dose-Response Relationship, Drug; D006801:Humans
D000991:Antithrombins; D052157:Aptamers, Nucleotide